{"page_content": "Appendix\n68  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nIntroduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen\nThis ESG Report is part of Amgen\u2019s overall commitment to providing robust reporting on our ESG performance  . We have also reported information in our Annual Report and 10-K, as well as our \nProxy Statement , which may be useful to our investor\u2019s understanding of our activities that support our ESG efforts  . As noted previously, this ESG Report was prepared in alignment with the \nBiopharma Sustainability Roundtable Investor ESG Communications Guidance , which considers key elements and principles of the Sustainability Accounting Standards Board (SASB) standard  \nfor the Biotechnology industry  .\nIn the table below we have indicated where Amgen reports on metrics that are included in the SASB standard, including sections of this Report, our website, our proxy statement and our \nperiodic filings with the Securities and Exchange Commission (SEC) .  Our ESG reporting continues to evolve and expand \u2013 as a result, where we have indicated that we do not report on a  \nmetric at this time, we will continue to evaluate our ability to report on that metric in the future  .SASB INDEX\nSASB TOPIC ACCOUNTING METRICUNIT OF\nMEASURECODE REPORTING\nSafety of Clinical \nTrial ParticipantsDiscussion, by world region, management process for  \nensuring quality and patient safety during clinical trialsn/a HC-BP-210 .a .1 Pertinent reporting can be found in the Product Quality \nand Patient Safety section of this Report; the Global Code \nof Ethics for Clinical Trials , Quality and Global Patient Safety \nsections of our website; and the Business and Risk Factors \nsection in Part I of the 10-K .\nNumber of FDA Sponsor Inspections related to clinical trial \nmanagement and pharmacovigilance that resulted in: (1) \nVoluntary Action Indicated (VAI) and (2) Official Action \nIndicated (OAI)Number HC-BP-210 .a .2 Amgen discloses material legal and regulatory issues in its \nannual 10-K and quarterly 10-Qs  .\nTotal amount of monetary losses as a result of  \nlegal proceedings associated with clinical trials  \nin developing countriesReporting currency HC-BP-210 .a .3 Amgen discloses material legal and regulatory issues in its \nannual 10-K and quarterly 10-Qs  .APPENDIX", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 67, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}